Weekly PSP Briefing — Ozempic

Week ending September 6, 2026

1. Self-management questions this week

• Dosing schedule and titration: The clearest self-management theme. Seven responses addressed, “What is the recommended starting dose…how do I increase it, and how often should I inject it?” Answers consistently described 0.25 mg once weekly for four weeks, followed by titration.
• Missed doses: Seven responses asked, “If I miss a dose…should I skip it or take it later?” This is the highest-priority practical issue because answers gave different timing windows.
• Side-effect and condition management: Seven responses covered kidney disease/worsening renal function, emphasizing hydration and monitoring when nausea, vomiting, or diarrhea occur. Seven more addressed suspected pancreatitis, generally advising urgent evaluation and holding/stopping the next dose.
• Injection technique, storage/handling: No literal questions were tagged this week on injection steps, pen use, needle handling, refrigeration, or storage. This is an absence in the monitored sample—not evidence that patients have no need.
• Other adjacent questions: Patients also asked about insulin/sulfonylurea-related low blood sugar, pregnancy/breastfeeding, and switching between semaglutide brands. These may generate hotline questions but are primarily medical-information topics.

2. Where guidance is inconsistent or thin

Highest priority: missed-dose guidance. Across seven answers, patients were variously told to take the dose if remembered within 48 hours, two days, or five days. Examples include “within 5 days (120 hours)” versus “if…more than 48 hours, skip.” This is a material adherence risk and could lead to unnecessary skipping or doses taken too close together. Update all onboarding, reminders, chatbot content, and nurse scripts to one approved, consistently worded instruction.

Dosing/titration answers were broadly aligned, but several added caveats such as “follow your prescriber’s plan” without directing patients to a practical support route. Overall, 73 hedging/disclaimer tags suggest frequent qualification; on day-to-day questions, this can feel like deflection when no concrete next step is provided.

3. Support-pathway visibility

Answers often say “ask your prescriber,” “tell me,” or “seek urgent medical evaluation.” None visibly connect patients to a nurse educator, PSP hotline, or support coordinator. Add a standard support invitation to onboarding and digital materials: who to call for missed-dose questions, injection coaching, side-effect self-management, and escalation.

4. Trend across weeks

Volume fell from 20 questions/120 responses last week to 12/81 this week; inconsistency flags fell from 32 to 22. The inconsistency rate per response is essentially steady, so the underlying guidance-quality issue remains. Dosing-related tags also declined with volume, while kidney and pregnancy-related themes were slightly higher than last week.

5. Recommended actions

1. Urgently harmonize missed-dose guidance across materials and hotline scripts.
2. Add a visible PSP contact pathway to onboarding, reminders, and digital answers.
3. Proactively offer nurse outreach to new starters covering titration, missed doses, hydration, and when to seek help.
4. No immediate storage/technique update based on this week’s data, but continue monitoring and retain existing injection/storage education.